newsfilter
← Latest News
Business Wire·

Bayer Shares New Post Hoc Analysis Of Self-Reported Sleep-Related Outcomes with Lynkuet® (elinzanetant) in Women with Moderate to Severe Vasomotor Symptoms at the Menopause Society Annual Meeting

Lynkuet® (elinzanetant) 60 mg capsules is a neurokinin 1 (NK1) receptor and NK3 receptor antagonist FDA-approved for the treatment of moderate to severe vasomotor symptoms (VMS), also known as hot flashes, due to